TRCT
UNCY icon

Tower Research Capital (TRC)’s Unicycive Therapeutics UNCY Stock Holding History

Tower Research Capital (TRC)’s Portfolio UNCY Stock Details UNCY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.39K Buy
+1,788
New +$13.2K ﹤0.01% 4077
2026
Q1 		– Sell
-1,920
Closed -$11.1K – 5581
2025
Q4 		$11.1K Buy
+1,920
New +$10.3K ﹤0.01% 3656
2025
Q1 		– Sell
-1,089
Closed -$8.64K – 5808
2024
Q4 		$8.64K Sell
1,089
-1,189
-52% -$6.58K ﹤0.01% 3979
2024
Q3 		$9.29K Buy
2,278
+429
+23% +$1.72K ﹤0.01% 3881
2024
Q2 		$9.26K Buy
1,849
+1,081
+141% +$10.6K ﹤0.01% 4272
2024
Q1 		$10.6K Buy
768
+92
+14% +$1.11K ﹤0.01% 3677
2023
Q4 		$5.87K Buy
676
+369
+120% +$2.41K ﹤0.01% 4796
2023
Q3 		$2.64K Buy
307
+100
+48% +$937 ﹤0.01% 5126
2023
Q2 		$2.65K Sell
207
-135
-39% -$2.11K ﹤0.01% 5172
2023
Q1 		$7K Sell
342
-158
-32% -$1.57K ﹤0.01% 4778
2022
Q4 		$3K Sell
500
-18
-3% -$122 ﹤0.01% 5244
2022
Q3 		$3K Buy
518
+1
+0.2% +$7 ﹤0.01% 5433
2022
Q2 		$4K Buy
517
+133
+35% +$1.27K ﹤0.01% 5260
2022
Q1 		$5K Buy
+384
New +$5.62K ﹤0.01% 5108

Other funds holding UNCY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DC
Diametric Capital Boston, Massachusetts $948M AUM 47.49% 1-Year Est. Return

Tower Research Capital (TRC)'s UNCY Position: Q2 2026 in Review

Tower Research Capital (TRC) opened a new position in Unicycive Therapeutics (UNCY) in Q2 2026: 1,788 shares worth $8.39K. The stake represents ﹤0.01% of the portfolio and ranks #4077 among its holdings. This is a return to the name: Tower Research Capital (TRC) previously reported a position in UNCY as recently as Q4 2025.

Tower Research Capital (TRC) first reported a position in UNCY in Q1 2022 and has held it in 14 quarters since. The position peaked at $11.1K in Q4 2025. 80 funds tracked by Wall St. Rank hold UNCY as of Q2 2026.

  • Tower Research Capital (TRC) held 1,788 shares of Unicycive Therapeutics worth $8.39K as of Q2 2026.
  • Unicycive Therapeutics was a new Tower Research Capital (TRC) position in Q2 2026.
  • Unicycive Therapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #4077 holding.
  • Tower Research Capital (TRC) first reported a position in Unicycive Therapeutics in Q1 2022 and has held it in 14 quarters since.
  • Tower Research Capital (TRC)'s Unicycive Therapeutics position peaked at $11.1K in Q4 2025.
  • 80 funds tracked by Wall St. Rank held Unicycive Therapeutics as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.